Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

J Transl Med. 2022 Jun 27;20(1):292. doi: 10.1186/s12967-022-03453-0.

Yali Yi^#^{1

2}, Jing Cai^#^{1

2}, Peng Xu^{1

2}, Le Xiong^{1

2}, Zhiqin Lu^{1

2}, Zhimin Zeng^{3

4}, Anwen Liu^{5

6}

¹ Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China.
² Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China.
³ Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China. 2zm@163.com.
⁴ Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China. 2zm@163.com.
⁵ Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China. awliu666@163.com.
⁶ Jiangxi Key Laboratory of Clinical Translational Cancer Research, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi Province, China. awliu666@163.com.

^# Contributed equally.

No abstract available

Publication types